UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 662

Sortiert nach

Nivolumab in NSCLC: latest evidence and clinical potential

Therapeutic Advances in Medical Oncology, 2015-03, Vol.7 (2), p.85-96

2015

Volltextzugriff (PDF)

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2016-03, Vol.93, p.59-68

2016

Volltextzugriff (PDF)

Immunotherapy in the treatment of non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.101-109

2014

Volltextzugriff (PDF)

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

Frontiers in oncology, 2023-03, Vol.13, p.1117348-1117348

2023

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100332-100332, Article 100332

2022

Volltextzugriff (PDF)

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib

Journal of clinical oncology, 2007-06, Vol.25 (18), p.2528-2533

2007

Volltextzugriff (PDF)

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Cancer treatment reviews, 2018-04, Vol.65, p.1-10

2018

Volltextzugriff (PDF)

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Volltextzugriff (PDF)

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1233-1243

2019

Volltextzugriff (PDF)

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1403-1410

2017

Volltextzugriff (PDF)

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The lancet oncology, 2021-07, Vol.22 (7), p.959-969

2021

Volltextzugriff (PDF)

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2019-12, Vol.105 (5), p.1065-1073

2019

Volltextzugriff (PDF)

Phase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type EGFR

The oncologist (Dayton, Ohio), 2014-07, Vol.19 (7), p.702-703

2014

Volltextzugriff (PDF)

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Experimental and Molecular Medicine, 2020, 52(0), , pp.1-14

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Lung cancer (Amsterdam, Netherlands), 2018-01, Vol.115, p.12-20

2018

Volltextzugriff (PDF)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-04, Vol.39 (11), p.1253-1263

2021

Volltextzugriff (PDF)

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Cancer discovery, 2020-08, Vol.10 (8), p.1194-1209

2020

Volltextzugriff (PDF)

Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute

Journal of surgical oncology, 2007-05, Vol.95 (6), p.461-468

2007

Volltextzugriff (PDF)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Volltextzugriff (PDF)

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Clinical cancer research, 2021-08, Vol.27 (15), p.4397-4409

2021

Volltextzugriff (PDF)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical cancer research, 2021-08, Vol.27 (15), p.4160-4167

2021

Volltextzugriff (PDF)

Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer

The Annals of thoracic surgery, 2011-02, Vol.91 (2), p.344-348

2011

Volltextzugriff (PDF)

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Naunyn-Schmiedeberg's archives of pharmacology, 2014-06, Vol.387 (6), p.505-521

2014

Volltextzugriff (PDF)

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer

Clinical cancer research, 2020-07, Vol.26 (13), p.3287-3295

2020

Volltextzugriff (PDF)

1 – 25 von 662

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(621)
Mit Volltextzugriff
(642)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(336)
Life Sciences & Biomedicine
(313)
Humans
(251)
Oncology
(249)
Female
(156)
Male
(150)
Middle Aged
(137)
Lung Neoplasms - Drug Therapy
(130)
Aged
(128)
Adult
(121)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(111)
Mutation
(99)
Lung Neoplasms - Genetics
(89)
Respiratory System
(83)
Lung Cancer
(80)
Carcinoma, Non-Small-Cell Lung - Genetics
(79)
Lung Neoplasms - Pathology
(77)
Tumors
(74)
Aged, 80 And Over
(67)
Carcinoma, Non-Small-Cell Lung - Pathology
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Nivolumab in NSCLC: latest evidence and clinical potential

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Immunotherapy in the treatment of non-small cell lung cancer

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type EGFR

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer

Suchergebnisse filtern